Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
FULVESTRANT
FORMATIVE PHARMA INC.
L02BA03
FULVESTRANT
50MG
SOLUTION
FULVESTRANT 50MG
INTRAMUSCULAR
15G/50G
Prescription
Active ingredient group (AIG) number: 0149744001; AHFS:
APPROVED
2023-10-13
Page 1 of 41 PRODUCT MONOGRAPH PR FULVESTRANT INJECTION 50 mg / mL Nonagonist Estrogen Receptor Antagonist FORMATIVE PHARMA INC. 4145 North Service Road, Suite 200 Burlington, Ontario, L7L 6A3 Date of Revision: September 18, 2023 Submission Control No: 275054 Page 2 of 41 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ...................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................... 3 CONTRAINDICATIONS ................................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................... 4 ADVERSE REACTIONS ................................................................................................. 6 DRUG INTERACTIONS................................................................................................ 13 DOSAGE AND ADMINISTRATION ........................................................................... 14 OVERDOSAGE .............................................................................................................. 17 ACTION AND CLINICAL PHARMACOLOGY .......................................................... 17 STORAGE AND STABILITY ....................................................................................... 20 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................... 20 PART II: SCIENTIFIC INFORMATION ............................................................................. 21 PHARMACEUTICAL INFORMATION ....................................................................... 21 CLINICAL TRIALS ....................................................................................................... 21 DETAILED PHARMACOLOGY .................................................................................. 35 TOXICOLOGY ........ Կարդացեք ամբողջական փաստաթուղթը